CorneaGen
  • SURGEON PORTAL
  • Contact Us
  • CORNEAL TISSUE
    • Tissue Overview
    • Tissue Services
      • DSAEK
      • DMEK
      • Geuder Pre-Loaded Glass Cannula
      • Ampho B
      • PKP
      • ALK
      • BrightMEM
      • FLAK
      • Non-Sterile Sclera
    • Tissue Reimbursement
    • Adverse Reaction Reporting
    • Regulatory Information
    • Request Tissue
  • Sterile Tissue
    • CTAK
    • VisionGraft
      • Glaucoma
      • Cornea
    • Sclera
    • Reimbursement
      • CTAK Reimbursement
      • VisionGraft Reimbursement
    • Adverse Reaction Reporting
    • Regulatory Information
  • CTAK
    • CTAK Overview
    • CTAK Reimbursement
  • Products
    • Products Overview
    • EndoSerter-PL
    • EndoSerter
    • Cannula
    • Geuder Pre-Loaded Glass Cannula
    • DescePro System
    • Donor Punch
    • Recipient Trephine
    • Intacs
  • Education
    • Educational Videos
    • Wet Labs
    • Fellows Program
  • About Us
    • Our People
    • Our Partners
    • Our Locations
    • Reimbursement
    • Gift of Sight
    • News & Events
    • Core Commitments
    • Innovation
    • Careers
Request Tissue Contact Us
Tom Frinzi

Tom Frinzi

September 30, 2020

Thomas Frinzi is the former Worldwide President, Surgical, Johnson & Johnson Vision business, which includes a broad ophthalmology portfolio across the areas of cataracts and refractive surgery (LASIK). Tom was appointed to his position in February 2017 at the conclusion of Johnson & Johnson’s acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. Mr. Frinzi joined AMO in January 2016 as Senior Vice President of Abbott Laboratories and President, Abbott Medical Optics.

Prior to joining Abbott, Mr. Frinzi held a number of leadership positions in ophthalmology and medical device companies. Most recently, he served as President and CEO of WaveTec Vision, a developer of surgical systems for eye surgery. He also held senior positions in commercial operations, business development, and sales and marketing at Bausch & Lomb Surgical, Refractec and Johnson & Johnson. In recognition of his leadership, expertise and vision in the field, Mr. Frinzi was awarded the 2015 Ophthalmology Innovation Award by the Ophthalmology Innovation Summit. He earned a bachelor’s degree in political science from the University of Tampa.

Recent Articles

  • CEO Update – June 2025

    CEO Update – June 2025

    A message from Bernie Iliakis, President & CEO of CorneaGen...

    READ MORE
  • Bernie’s Quarterly Update – November 2024

    Bernie’s Quarterly Update – November 2024

    A message from Bernie Iliakis, President & CEO of CorneaGen...

    READ MORE
  • Bernie’s Quarterly Update – July 2024

    Bernie’s Quarterly Update – July 2024

    A message from Bernie Iliakis, President & CEO of CorneaGen...

    READ MORE
  • CorneaGen Launches CTAK, an Innovation for Improved Patient Outcomes

    CorneaGen Launches CTAK, an Innovation for Improved Patient Outcomes

    CorneaGen Launches CTAK, an Innovation for Improved Patient Outcomes Advanced...

    READ MORE
Navigation
  • Corneal Tissue
  • Products
  • Innovation
  • Education
  • About Us
  • Request Tissue
Helpful Information
  • Reimbursement assistance
  • Adverse reaction reporting
  • KAMRA Support
  • Careers
Legal
  • Privacy Policy
  • Terms and conditions
  • Regulatory Information
Connect
  • Contact Us
CorneaGen

©2025 CorneaGen

CorneaGen